FDA's Rare Disease Drug Crackdown Signals Coming Showdown Between Industry, Advocates, and Trump Administration

The Current Landscape: A Dramatic Shift at FDA

The U.S. Food and Drug Administration under Commissioner Marty Makary and medical chief Vinay Prasad has embarked on a dramatic reversal of its approach to rare disease therapies, rejecting at least five cell and gene therapies since the Trump administration installed new leadership. These rejections represent a fundamental shift in regulatory philosophy—one that is raising alarm bells across the rare disease community while simultaneously opening new channels for pharmaceutical industry lobbying. The most striking case involves Atara Biotherapeutics' Ebvallo, a cell therapy for a rare post-transplant blood cancer that affects only 500 U.S. patients annually. According to Article 6, internal FDA reviewers had recommended approval, yet the agency ultimately rejected it—a decision that a former FDA employee called a "complete reversal" attributable to new leadership. Similarly, Article 5 details how Regenxbio's gene therapy for mucopolysaccharidosis (MPS) type 2 was rejected this month, devastating families like the Selsers who had been given hope after early diagnosis. Makary has defended these decisions aggressively. In an interview covered in Articles 1 and 2, he called Prasad a "genius" facing a "fatwa" and "smear campaign," while characterizing one rejected therapy as requiring researchers to "drill a burr hole, literally a hole in people's skulls" with no demonstrated benefit.

The Paradox: Political FDA Meets Industry Lobbying

A fascinating contradiction has emerged: while HHS Secretary Robert F. Kennedy Jr. promises to "root out industry influence" from FDA, the Trump administration's unprecedented politicization of the agency has actually created new lobbying opportunities. Articles 10 and 11 reveal that pharmaceutical companies dramatically increased spending on Trump-connected lobbying firms—with three firms (Checkmate Government Relations, Miller Strategies, and Ballard Partners) drawing a combined $11.7 million from pharma clients in 2025, up from just $2.2 million in 2024. As one managing partner told Article 11, "The nature of the relationship is so drastically different now," with discussions about FDA decisions that once would have been "heretical" now becoming the norm. Lobbyists believe "the odds of approval go up if a decision can be spun as a win for the Trump administration."

What Happens Next: Five Key Predictions

### 1. Congressional Intervention on Rare Disease Approvals The rare disease patient advocacy community is mobilizing, and their political power should not be underestimated. Article 5 captures the emotional intensity of families who feel betrayed by shifting FDA signals. Expect bipartisan congressional pressure to mount within the next 2-3 months, potentially including hearings specifically examining the Ebvallo and Regenxbio rejections. Patient advocacy groups will likely find receptive audiences among both Republican and Democratic lawmakers who traditionally support rare disease initiatives. ### 2. A High-Profile Approval Reversal or Expedited Review The FDA leadership faces a credibility crisis. Article 3's headline directly states that the "rejection is a reality check on agency rhetoric." To defuse mounting criticism, the agency will likely expedite approval of at least one previously-rejected rare disease therapy within 3-6 months, possibly after companies provide minimal additional data. This will be framed as evidence that the "higher standards" are still achievable, not prohibitive. ### 3. Pharmaceutical Industry's Two-Track Strategy Intensifies Companies will increasingly pursue dual strategies: maintaining traditional regulatory pathways while simultaneously deploying Trump-connected lobbyists to frame their products as administration priorities. The 16 companies that signed drug pricing deals with the White House (Article 10) have already demonstrated this playbook. Expect more drug pricing concessions to be bundled with implicit understandings about favorable regulatory treatment. ### 4. Vinay Prasad Becomes Lightning Rod Makary's defensive characterization of criticism against Prasad as a "smear campaign" (Articles 1 and 2) suggests leadership recognizes his vulnerability. As rejections mount and families share heartbreaking stories like Ben Selser's, Prasad will face intensifying scrutiny. Within 6 months, either Prasad will be repositioned to a less visible role, or the administration will double down with him as the face of "evidence-based" regulation—there is no middle ground. ### 5. Legal Challenges to Regulatory Process Changes Article 5 notes that UniQure says the FDA "suddenly changed course" on clinical trial design adequacy for its Huntington's gene therapy. Such mid-process reversals create legal vulnerabilities. Expect at least one rejected company to file suit within 3-6 months challenging the procedural legitimacy of how these decisions were made, particularly focusing on whether political appointees improperly overrode career scientists' recommendations.

The Underlying Dynamics

This story represents a collision between three forces: (1) an administration seeking to demonstrate "tough" regulatory oversight while claiming credit for lower drug prices, (2) a pharmaceutical industry adapting by increasing political spending and seeking to frame approvals as Trump victories, and (3) desperate patient communities caught in the middle. The most likely outcome is an unstable equilibrium where case-by-case political considerations increasingly trump (no pun intended) consistent scientific standards. The FDA's traditional insulation from political pressure—built over decades precisely to prevent such scenarios—is being systematically dismantled. Whether this represents a temporary disruption or permanent transformation depends largely on how effectively rare disease advocates can mobilize political pressure and whether the pharmaceutical industry's lobbying creates a backlash. The next 3-6 months will be critical in determining whether the FDA can maintain any semblance of scientific independence, or whether drug approvals become just another chip in broader political negotiations.